Vedanta sets May 1 as record date for demerger; approves 1:1 share allotment across 4 entities

Anil Agarwal-led Vedanta shares fall after ED searches at company premises

The Enforcement Directorate has conducted search operations across Vedanta Ltd.’s offices in Mumbai and Delhi, sources with knowledge of the matter told CNBC-TV18 on Tuesday, June 2. These search operations are being carried out with regards to the royalty payment made by Vedanta Ltd. to its parent company Vedanta Resources. “We are extending full cooperation…

Read More
Midcap Stocks: Volatility or opportunity? 5 picks across sectors offer upside potential of up to 40% - Do you own any? | LIST - Markets

Midcap Stocks: Volatility or opportunity? 5 picks across sectors offer upside potential of up to 40% – Do you own any? | LIST – Markets

Midcap Stocks: The probability of portfolio values declining from current levels in the short term is being viewed as higher than the likelihood of an easy rebound, as markets adjust to the prospect of weaker near-term corporate earnings. Analysts indicate that pressure on earnings could become visible in the first quarter of FY27 and potentially…

Read More
Trade Setup for April 2: Nifty sees a relief rally but 23,000 remains a barrier

Trade Setup for June 3: Nifty holds key support but overall trend remains choppy

The Nifty50 snapped its recent losing streak in Thursday’s expiry session, staging a strong recovery after a weak start. The benchmark index opened with a gap-down and tested its previous swing-low support level, which also marked the day’s low. Buyers stepped in at lower levels and successfully defended key support zones, triggering a sharp rebound…

Read More
Investment Strategy at 50: Lump Sum or SIP? 9 funds recommended by expert to plan smart and balance risk - Mutual Funds

Sensex Prediction for Wednesday by experts: Index rebound set to face vital 75000 hurdle on June 3; key technical levels to watch – Markets

Sensex Prediction for Wednesday, June 3 by experts: Technical experts are predicting a cautiously bullish to neutral session as the benchmark index attempts to reclaim the psychologically vital 75,000 mark, backed by a powerful rally in IT shares. Sensex Prediction for Wednesday, June 3 by experts: After a spectacular 1,047.07 points intraday high on Tuesday,…

Read More
SEBI may ease borrowing rules to give mutual funds more flexibility in managing cash

Govt begins search for 2 whole-time Sebi members; invites applications

The government has invited applications to fill two whole-time member posts at the markets regulator Securities and Exchange Board of India (Sebi). Currently, there are four whole-time members (WTMs), including Kamlesh Chandra Varshney, Amarjeet Singh, Sandip Pradhan and KVR Murty. Varshney and Singh will complete their three-year tenure in September, although they are eligible for…

Read More
John Cockerill India bags ₹440–470 crore order from JSW Steel Coated Products

John Cockerill India, subsidiary win order worth up to 1,300 cr from JSW Vijayanagar

Industrial engineering company John Cockerill India Ltd and its wholly-owned subsidiary John Cockerill Metal International SA have received a contract from JSW Vijayanagar Metallics for the design, engineering, supply, building supervision and commissioning of annealing and pickling lines for a CRNO project. The aggregate contract value is estimated at ₹1,250-1,300 crore. John Cockerill India on…

Read More
Oyo IPO soon? Parent Prism gets Sebi's nod to launch Rs 6,650-cr public issue - Details - Markets

Oyo IPO soon? Parent Prism gets Sebi’s nod to launch Rs 6,650-cr public issue – Details – Markets

Prism, the parent firm of global travel tech unicorn Oyo, has received the approval of the markets regulator Sebi to raise Rs 6,650 crore through its initial public offering (IPO), people familiar with the development said on Tuesday, as reported by news agency PTI. Earlier in December-end 2025, OYO’s parent entity PRISM filed the preliminary…

Read More
Concord Biotech gets FDA nod for immunosuppressant mycophenolate mofetil

Concord Biotech gets FDA nod for immunosuppressant mycophenolate mofetil

Pharmaceutical company Concord Biotech Ltd on Tuesday (June 2) said it has received approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for mycophenolate mofetil for oral suspension USP, 200 mg/mL. The company said mycophenolate mofetil is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in…

Read More